Medical research testing ©Pixnio Novo Nordisk (NYSE:NVO) shares declined 6% on Monday after the Danish pharmaceutical company presented its long-term strategy and financial ambitions at a capital markets day in London. The company expects compound annual revenue growth between 2026 and 2030 to be in line with that of its industry peers, while maintaining a broadly stable operating margin. Both objectives are based on adjusted financial measures. Novo Nordisk emphasised that the targets represent strategic ambitions rather than formal financial guidance. Drug Pipeline Expected to Support Long-Term Growth Novo Nordisk aims to launch more than five medicines with the potential to achieve blockbuster sales across multiple indications by 2030.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.